Requesting Cell-lines : List of All Available Lines

QuickLinks:   Home » Protocols » Request Cell Lines » Download MTA » Contact

Investigators may request up to 3 cell lines (cumulative overall requests) with minimal paper work. Between 3 and 10 lines requires justification and local review and >10 lines requires a formal application and approval by the appropriate COG committee.

The prioritization of how material is distributed will be determined by the COG Disease Committees and the COG Biology and Translational Research Committee.

Some previously published cell lines, with originating investigator approval, will be characterized by the COG Cell Culture and Xenograft Repository laboratories, and made available through this web site.

Questions about the Cell Culture and Xenograft Repository can be directed to CellRequest@cogcell.org.

As of February 2011, a revised MTA was finalized to encompass most concerns that were raised in the past. The MTA is final and no changes will be possible. If you still have questions regarding the MTA, you can email CellLineInfo@cogcell.org for clarification.

Print the form, fill in your request, sign it, and either scan it to PDF format for sending to us (using the upload button on the cell request form), or fax it to 806-743-2691.

Please contact CellLineInfo@cogcell.org if you are requesting cell lines that are not currently on the Open Distribution List.

Requesting All Cell Lines

Select the cell lines wanted (requesting > 3 lines requires protocol approval) :

Select by clicking on the checkbox for the cell lines you want.

To deselect, just click on the checkbox a second time.

To view a complete cell line description (origin, growth conditions, pictures, etc.), click on the cell line name to open a pdf data sheet to view and/or download.

To view a characterization table of the EFT cell lines, click here.

Please visit the COGcell.org website frequently, as cell line data is continually being updated and new cell lines are added.

All cell lines were established in 20% O2 unless otherwise noted. Cell lines ending in "h" designates cell line was established in hypoxic conditions (5% O2 tension).

Brain Tumor Lines

Request Cell Line Disease Diagnosis Gender Age (Years) Phase of Therapy1 Site of specimen DT5 (hours) References
BT-12* Brain Tumor Atypical teratoid/rhabdoid F 0.2 Dx     44,PPTP
CHLA-200 Brain Tumor Glioblastoma multiforme M 12 PD-PM Parietal lobe 54 9
CHLA-259 Brain Tumor Anaplastic medullablastoma M 14 Dx Posterior fossa 76 9
CHLA-266* Brain Tumor Atypical teratoid/rhabdoid F 1.5 DX posterior fossa 45 9,46,PPTP
SJ-GBM2* Brain Tumor Glioblastoma multiforme F 5 PD brain   45,PPTP

Ewing's Family of Tumors Lines

Request Cell Line Disease Diagnosis Age (Years) Phase of Therapy1 EWS/FLI1 Status4 p53 Status3 DT5 (hours) References
CHLA-9* Ewing's Family of Tumors PNET 14 Dx FLI1 F 51 22,PPTP
CHLA-10* Ewing's Family of Tumors PNET 14 PD FLI1 N 32 12,22,PPTP
CHLA-25 Ewing's Family of Tumors PNET 2.6 PD ERG N 99  
CHLA-32 Ewing's Family of Tumors PNET 8.5 Dx FLI1 F 26 22
CHLA-258* Ewing's Family of Tumors PNET 14 PD FLI1 N 89 22,PPTP
COG-E-352 Ewing's Family of Tumors PNET 17 PD-PM ERG N 28 22,PPTP
TC-32 Ewing's Family of Tumors PNET 17 Dx FLI1 N 24 3,6,22,24,25
TC-71* Ewing's Family of Tumors Ewing's Sarcoma 22 PD FLI1 N 21 6,22,23,25,
47,PPTP

Leukemia Lines

Request Cell Line Disease Diagnosis Gender Age (Years) Phase of Therapy1 Site of Specimen DT5 (hours) References
COG-LL-317* Leukemia T-cell ALL M 1.7 PD Bone marrow 30-40 26,27,28,49,
PPTP
COG-LL-317h* Leukemia T-cell ALL M 1.7 PD Bone marrow 19-20 26,27,49,
PPTP
COG-LL-319h Leukemia Pre-B ALL F 13 Dx Bone marrow 50-62 26,27,28,49,
PPTP
COG-LL-329h Leukemia T-cell ALL     Dx Bone marrow   28
COG-LL-332h Leukemia T-cell ALL M 10 PD Bone marrow 30-34 28,49
COG-LL-355h Leukemia Pre-B ALL     Dx Bone marrow   28
COG-LL-356h Leukemia Pre-B ALL     Dx Bone marrow   28
COG-LL-384h Leukemia T-cell ALL     PD Bone marrow   28

Neuroblastoma Lines

Request Cell Line Disease Stage Age (Months) Phase of Therapy1 MYCN Status2 p53 Status3 DT5 (hours) References
CHLA-15 Neuroblastoma 4 18 DX N F 21 5,10,12,14,
17,20,21
CHLA-20 Neuroblastoma 4 18 PD N F 28 5,10,17,21
CHLA-42 Neuroblastoma 4 13 Dx N     5,10,12,17,
21
CHLA-90 Neuroblastoma 4 102 PD-BMT N N 59 2,5,10,12,
14,16,18
CHLA-95 Neuroblastoma 4   PD A     12
CHLA-122 Neuroblastoma 4 24 Dx   F 72 2,17,21
CHLA-136 Neuroblastoma 4 36 PD-BMT A F 44 2,12,17
CHLA-140 Neuroblastoma 4   PD N     10,12,17,18
CHLA-171 Neuroblastoma 4   PD N N   2,12,14,17
LA-N-5 Neuroblastoma   5 Dx A   100 3,6,12,16,24
LA-N-6 Neuroblastoma 4 60 PD N F 150 2,3,4,5,6,
10,12,17
NB-1643* Neuroblastoma 4 < 36 Dx A     48,PPTP
NB-EBc1* Neuroblastoma 4 < 36 PD N     48,PPTP
SK-N-BE(1) Neuroblastoma 4 24 Dx A F 96 2,3,5,8,10,
12,14
SK-N-BE(2) Neuroblastoma 4 24 PD A N 27 2,3,5,8,10,
14,17,20
SK-N-FI Neuroblastoma   264   N     3,6,12
SMS-KAN Neuroblastoma 4 36 Dx A F 95 1,3,5,6,10,
12,16,24
SMS-KANR Neuroblastoma 4 36 PD A F 69 1,3,5,10,16
SMS-KCN Neuroblastoma 4 11 Dx A F 109 1,3,5,10,24
SMS-KCNR Neuroblastoma 4 11 PD A F 72 1,2,3,5,6,
10,16,17,
18,20,21,
24
SMS-LHN Neuroblastoma 4 24 PD N F 216 2,3,4,5,6,
10,17
SMS-SAN Neuroblastoma 4 36 Dx A F 71 1,2,3,5,6,
10,14,17,
19,21,24

Rhabdomyosarcoma Lines

Request Cell Line Disease Diagnosis Age (Years) Phase of Therapy1 p53 Status3 Site of specimen DT5 (hours) References
Rh18* Rhabdomyosarcoma embryonal 2 Dx N perineum 65 42,PPTP
Rh30* Rhabdomyosarcoma alveolar 16 Dx F bone marrow 35 41,PPTP
Rh41* Rhabdomyosarcoma alveolar   PD N lung 60 43,PPTP

1 - Phase of therapy for the patient at the time the specimen used to derive the cell line was obtained
Dx (Diagnosis): cell lines derived from samples of patients prior to treatment
PD (Progressive Disease): cell lines derived from samples of patients who relapsed after chemotherapy
PD-BMT: cell lines derived from samples of patients who relapsed after chemotherapy and bone marrow transplantation
PD-PM: cell lines derived from samples of post-mortem patients who relapsed after chemotherapy

2 - N-Myc oncogene amplification
N: MYCN Non-Amplified
A: MYCN Amplified

3 - p53 gene function
F: Functional
N: Non-Functional

4 - EWS/FLI1 Status
FLI1: friend leukemia insertion - chromosome 11, t(11;22)
ERG: ets-related gene - chromosome 21, t(21;22)

5 - Doubling Time

* - NCI PPTP Cell Lines

For details on all the NCI PPTP cell lines see:

Kang MH, Smith MA, Morton CL, Nino Keshelava N, Houghton PJ, Reynolds CP: National Cancer Institute Pediatric Preclinical Testing Program: Model description for in vitro cytotoxicity testing. Pediatr Blood Cancer 56:239-49, 2011.

Please enter your name:

Please enter your telephone number:

Please enter your complete shipping address:

Please enter your email address:

Please enter your Institution:

Please provide the name of your courier (eg. FedEx, Airborne, UPS) if available:
(nb. Please do not specify DHL as we are not able to use DHL for shipments.)

Please provide your FedEx or other courier account number (if available):

If you are requesting more than 3 cell lines:
Who should review the proposal? (Please select one)

The Disease Committee (for requests of material of a single disease)

The Biology and Translational Research Committee (for requests of material from multiple diseases)

If you are requesting 3-10 cell lines, upload a < 1 page description of research and justification for the lines.

(PDF format only; maximum allowed file size is 2 megabytes)

If you are requesting more than 10 lines, upload a full COG biology specimen application form.

(PDF format only; maximum allowed file size is 2 megabytes)

Upload your COG Specimen Transfer Agreement:

(PDF format only; maximum allowed file size is 2 megabytes)

You can also FAX this form to 806-743-2691 if you have difficulty uploading it.

Do you have any special requests or comments? If so, please enter them here.
 

© Texas Tech University Health Sciences Center (2008-2011)
Shown are confocal images of CHLA-90 (above), and FU-NB-2006 (left).
Confocal images by Felicia Codrea.